B. Kilgallen

913 total citations
11 papers, 684 citations indexed

About

B. Kilgallen is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, B. Kilgallen has authored 11 papers receiving a total of 684 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Rheumatology, 8 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Immunology. Recurrent topics in B. Kilgallen's work include Systemic Lupus Erythematosus Research (9 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and T-cell and B-cell Immunology (4 papers). B. Kilgallen is often cited by papers focused on Systemic Lupus Erythematosus Research (9 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and T-cell and B-cell Immunology (4 papers). B. Kilgallen collaborates with scholars based in United States, Belgium and United Kingdom. B. Kilgallen's co-authors include Kenneth Kalunian, Michelle Petri, Caroline Gordon, Daniel J. Wallace, Vibeke Strand, Sabine Bongardt, Marilyn C. Pike, Frédéric Houssiau, Kathryn Hobbs and C. Stach and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Arthritis & Rheumatology.

In The Last Decade

B. Kilgallen

11 papers receiving 669 citations

Peers

B. Kilgallen

RHEUM

IMMUN

RNMI

ONCOL

GENET

Kate Franklyn Australia

D. van Schaardenburg Netherlands

Francesca Saccon Italy

L De Rycke Belgium

Shereen Oon Australia

T Jonsdottir Sweden

Michel Tsang-A-Sjoe Netherlands

Maiko Yoshikawa Japan

Marina Stanislav Russia

Victoria Bejarano United Kingdom

Kate Franklyn Australia

B. Kilgallen

467 ×0.8

RHEUM

291 ×0.7

IMMUN

173 ×0.5

RNMI

57 ×0.7

ONCOL

28 ×0.4

GENET

Citations per year, relative to B. Kilgallen B. Kilgallen (= 1×) peers Kate Franklyn

Countries citing papers authored by B. Kilgallen

Since Specialization

Citations

This map shows the geographic impact of B. Kilgallen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Kilgallen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Kilgallen more than expected).

Fields of papers citing papers by B. Kilgallen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Kilgallen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Kilgallen. The network helps show where B. Kilgallen may publish in the future.

Co-authorship network of co-authors of B. Kilgallen

This figure shows the co-authorship network connecting the top 25 collaborators of B. Kilgallen. A scholar is included among the top collaborators of B. Kilgallen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Kilgallen. B. Kilgallen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Stach, C., Victor S. Sloan, Thasia Woodworth, B. Kilgallen, & Daniel E. Furst. (2019). Rheumatology Common Toxicity Criteria (RCTC): An Update Reflecting Real-World Use. Drug Safety. 42(12). 1499–1506. 12 indexed citations

Deodhar, Atul, Lianne S. Gensler, Jonathan Kay, et al.. (2019). A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. Arthritis & Rheumatology. 71(7). 1101–1111. 66 indexed citations

Clowse, Megan E. B., Daniel J. Wallace, Richard Furie, et al.. (2016). Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials. Arthritis & Rheumatology. 69(2). 362–375. 169 indexed citations

Wallace, Daniel J., Kathryn Hobbs, Megan E. B. Clowse, et al.. (2015). Long‐Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate‐to‐ Severe Systemic Lupus Erythematosus: Results From an Open‐Label Extension Study. Arthritis Care & Research. 68(4). 534–543. 33 indexed citations

Shock, Anthony, B. Kilgallen, C. Stach, et al.. (2015). FRI0002 Pharmacodynamic Effects of the CD22-Targeted Monoclonal Antibody Epratuzumab on B Cells in Cynomolgus Monkeys and in Patients with Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases. 74. 420–420. 2 indexed citations

Wallace, Daniel J., Kenneth Kalunian, Michelle Petri, et al.. (2013). Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Annals of the Rheumatic Diseases. 73(1). 183–190. 250 indexed citations

Wallace, Daniel J., Caroline Gordon, Vibeke Strand, et al.. (2013). Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Lara D. Veeken. 52(7). 1313–1322. 97 indexed citations

Strand, Vibeke, Michelle Petri, Kenneth Kalunian, et al.. (2013). Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Lara D. Veeken. 53(3). 502–511. 50 indexed citations

Gordon, Caroline, Megan E. B. Clowse, Frédéric Houssiau, et al.. (2013). THU0272 Epratuzumab Maintains Improvements in Disease Activity for Over 2 Years in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long-Term Extension Study (Sl0008). Annals of the Rheumatic Diseases. 72. A257–A257. 3 indexed citations

10.

Wallace, Daniel J., José Ordi-Ros, Kenneth Kalunian, et al.. (2013). THU0277 Epratuzumab: Sustained Safety Profile and Effect on Corticosteroid Use on Long-Term Treatment in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long-Term Extension Study (Sl0008). Annals of the Rheumatic Diseases. 72. A259–A259. 1 indexed citations

11.

Strand, Vibeke, Kenneth Kalunian, Daniel J. Wallace, et al.. (2012). AB0633 Epratuzumab-treated SLE patients report improvements in health-related quality of life: Interim results from a us open-label extension study. Annals of the Rheumatic Diseases. 71. 675–675. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact